April 27, 2015 – News Bytes

Drug Sponsors

Perrigo rejects Mylan’s second unsolicited offer

Dublin-based Perrigo has rejected a second unsolicited offer from Mylan to acquire all outstanding shares of Perrigo for $60 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share. Mylan is seeking to ward off an unsolicited offer from Israel-based Teva.  


The Pulse on Global Trials by Matthew Howes

Since being named “Breakthrough of the Year” by Science magazine less than two years ago, cancer immunology has been taken from the fringe to the forefront. 


More Pulse articles... »
Quest Diagnostics
CWWeekly

April 27

Doctors, patients in the U.S. and U.K. agree: Mobile health apps are good for our health

AARP teams with Georgia Tech's HomeLab, Pfizer and UnitedHealthcare to test wearables with consumers 50+

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.